ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2016

Jan 5, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2015-12-30

Reporting Person: Myszkowski Kenneth Allen (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-12-30	Common Stock	F	13153	$6.13	Disposed	108347	Direct
2015-12-30	Common Stock	S	23347	$6.13	Disposed	85000	Direct
2016-01-01	Common Stock	A	50000	$0.00	Acquired	135000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-01	Stock Option	$6.15	A	40000	Acquired	2026-01-01	Common Stock (40000)	Direct

Footnotes

F1: Represents shares underlying a restricted stock unit, which shares will vest in three equal annual installments on the anniversary date of the grant.

F2: Option vests and becomes exercisable over a four year period from date of grant.